Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma

CONCLUSION: The combination of HAIC-FOLFOX with lenvatinib and PD-1 inhibitors as a first-line therapy has exhibited notable therapeutic efficacy and well-tolerated adverse events among patients with high-burden HCC.PMID:38686567 | DOI:10.1002/cam4.7105

Source: Cancer Control - April 30, 2024 Category: Cancer & Oncology Authors: Shumin Fu Yongkang Xu Ye Mao Mengting He Zhimeng Chen Shenglan Huang Dan Li Yaqin Lv Jianbing Wu Source Type: research